Urologic Oncologists Seldom Perform Female Organ- and Nerve-Sparing Radical Cystectomy
Provider training on female reproductive organ-sparing and nerve-sparing radical cystectomy needs to improve, according to investigators.
Diagnosis & Disease Information
Radical Cystectomy Increases Risks for Thromboembolic Events
Swedish studies reveal significantly elevated risks for myocardial infarction, ischemic stroke, pulmonary embolism, and deep vein thrombosis.
Survival Improving in Metastatic Bladder Cancer Cases
Trend may reflect increasing use of systemic immunotherapies as first-line treatments, according to investigators.
Aortic Calcification Ups Risk for Acute Kidney Injury After Radical Cystectomy
Aortic calcification may lead to arterial degradation that increases the risk for acute kidney injury, according to investigators.
Prostate Cancer Found at Radical Cystectomy Usually Clinically Insignificant
Findings are from a case series of men who underwent cystoprostatectomy in China.
Pembrolizumab Could Meet Unmet Need in BCG-Unresponsive High-Risk NMIBC
Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.
Sequential Gemcitabine+Docetaxel an Effective Alternative to BCG in High-Risk NMIBC
Study findings fill in the evidence gap during the current BCG shortage, while data from randomized clinical trials are pending.
Sacituzumab Govitecan Elicits Responses in Platinum-Ineligible Metastatic Urothelial Carcinoma
Sacituzumab govitecan has demonstrated activity in patients with platinum-ineligible metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy.
Pre-Cystectomy Neoadjuvant Chemotherapy Risks, Benefits Characterized
Neoadjuvant chemotherapy prior to radical cystectomy is not associated with an increased risk for major complications vs radical cystectomy alone, but it does increase the risk for bleeding requiring transfusion and sepsis.
Photodynamic Therapy Shows Benefit in BCG-Unresponsive NMIBC
Investigators reported 90- and 450-day complete response rates of 53% and 28%, respectively, according to interim results from a phase 2 trial.
- Loading...
Loading...
Next post in Genitourinary Cancers Symposium
Loading... 
Loading...